Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
37 pending office actions • 22 art units • 35 examiners • 0 of 37 (0%) have an AI response strategy ready • 51 patents granted in the last 365 days
Memorial Sloan Kettering Cancer Center is managing a large portfolio of 36 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 34 distinct examiners and 22 distinct art units. KHOA NHAT TRAN is the busiest examiner, currently handling 2 pending office actions. The high number of 22 distinct art units reflects a very broad research and development focus. With 34 distinct examiners involved, the prosecution strategy must be highly decentralized. Practitioners will need to tailor their approach to a wide variety of examiner styles.
The fact that the busiest examiner, KHOA NHAT TRAN, only handles 2 pending office actions underscores the extreme distribution of this portfolio. With 36 pending office actions in total, the center is engaging with nearly as many distinct examiners. The 22 distinct art units suggest that the Biotechnology & Pharmaceuticals filings cover an expansive range of medical and scientific disciplines. This complexity requires practitioners to maintain 34 separate examiner relationships while navigating the specific requirements of the various art units. The current volume of prosecution demands significant coordination across the portfolio.
Based on the USPTO statutory response window for each pending office action. 15 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 15 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (11%) |
| §103 only | 7 (19%) |
| §102 only | 2 (5%) |
| §112 only | 6 (16%) |
| Double-patenting + other | 5 (14%) |
| Multi-statute (no §101) | 12 (32%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 2 | 43.2% | +53.3% |
| DIBRINO, MARIANNE | 2 | 42.8% | +42.2% |
| NEAGU, IRINA | 1 | 46.8% | +57.3% |
| DHAR, MATASHA | 1 | 43.3% | +45.7% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.2% | +43.4% |
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
| ANGELL, JON E | 1 | 71.0% | +21.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 91d overdue |
| 18003646 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | POPA, ILEANA | 15d |
| 17890694 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL | BUCHANAN, BAILEY CHEYENNE | 34d |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | — |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | DIBRINO, MARIANNE | — |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | TRAN, KHOA NHAT | — |
| 17095216 | METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS | SINGH, ANOOP KUMAR | — |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | ANGELL, JON E | 156d overdue |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | JOHANSEN, PETER N. | 28d |
| 17890694 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL | BUCHANAN, BAILEY CHEYENNE | 34d |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | BURKHART, MICHAEL D | 41d |
| 17426728 | SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER | DIBRINO, MARIANNE | 79d |
| 18947597 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | NEAGU, IRINA | — |
| 18799294 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | DHAR, MATASHA | — |
| 18188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 4 |
| 1632 | 3 |
| 1643 | 3 |
| 1682 | 2 |
| 1637 | 2 |
| 1633 | 2 |
| 1641 | 2 |
| 1642 | 2 |
| 1631 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947597 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | NEAGU, IRINA | — | §103 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18799294 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | DHAR, MATASHA | — | §112DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18506518 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | 28d | Pending | Nov 10, 2023 |
| 18188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | ZHU, JIANJIAN | 1631 | §103DP | Non-Final OA | — | Pending | Mar 23, 2023 |
| 18182258 | METHOD TO REDUCE ONCOGENIC POTENTIAL OF INDUCED PLURIPOTENT STEM CELLS FROM AGED DONORS | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18118072 | METHODS AND COMPOSITIONS FOR DETECTING RISK OF CANCER RELAPSE | BURKHART, MICHAEL D | 1638 | §112 | Non-Final OA | 41d | Pending | Mar 06, 2023 |
| 17890694 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§112Other | Non-Final OA | 34d | Pending | Aug 18, 2022 |
| 17697044 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION | ANGELL, JON E | 1637 | §112 | Final Rejection | 156d overdue | Pending | Mar 17, 2022 |
| 17697028 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §101§103§112 | Non-Final OA | 91d overdue | Pending | Mar 17, 2022 |
| 17681113 | METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17526812 | MESOTHELIN CARS AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §103§112Other | Final Rejection | — | Pending | Nov 15, 2021 |
| 17514742 | NON-INVASIVE METHODS FOR SELECTIVELY ENRICHING PLURIPOTENT CELLS | TICHY, JENNIFER M.H. | 1653 | §103DP | Final Rejection | 4d overdue | Pending | Oct 29, 2021 |
| 17405613 | COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY | GEORGE, DENNIS CHERIAN | 1644 | §103§112DP | Final Rejection | — | Pending | Aug 18, 2021 |
| 17400689 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | WU, JULIE ZHEN QIN | 1643 | §103 | Final Rejection | 33d | Pending | Aug 12, 2021 |
| 17319495 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS | TRAN, KHOA NHAT | 1632 | §101§103§112 | Final Rejection | — | Pending | May 13, 2021 |
| 17095216 | METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2020 |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | ZOU, NIANXIANG | 1671 | §103§112Other | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | 1674 | §102§112 | Non-Final OA | — | Pending | May 04, 2024 |
| 18392127 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MOSELEY II, NELSON B | — | §103DP | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18501782 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY | BRISTOL, LYNN ANNE | 1643 | §102§112Other | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18250607 | PATIENT-SPECIFIC THERAPEUTIC PREDICTIONS THROUGH ANALYSIS OF FREE TEXT AND STRUCTURED PATIENT RECORDS | WASEEM, HUMA | 3686 | §101§103 | Final Rejection | — | Pending | Apr 26, 2023 |
| 18249248 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2023 |
| 18043527 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | DUFFY, BRADLEY | 1643 | §102 | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18003646 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | POPA, ILEANA | 1633 | §103§112 | Non-Final OA | 15d | Pending | Dec 28, 2022 |
| 17911093 | DIGITAL PATHOLOGY RECORDS DATABASE MANAGEMENT | WORKU, SARON MATTHEWOS | 2408 | §103 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17909310 | ANTI-CCR8 AGENTS | SULLIVAN, DENNIS JOHN | 1642 | §112 | Final Rejection | 14d | Pending | Sep 02, 2022 |
| 17794340 | INTRAOPERATIVE 2D/3D IMAGING PLATFORM | RAYMOND, KEITH MICHAEL | 3798 | §103§112 | Final Rejection | — | Pending | Jul 21, 2022 |
| 17814205 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | SKELDING, ZACHARY S | 1644 | Other | Non-Final OA | 56d overdue | Pending | Jul 21, 2022 |
| 17745588 | DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY | OUSPENSKI, ILIA I | 1644 | §102§112 | Non-Final OA | — | Pending | May 16, 2022 |
| 17626941 | METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY | LU, CHENG | 1642 | §103§112 | Non-Final OA | — | Pending | Jan 13, 2022 |
| 17549811 | METHODS AND COMPOSITIONS FOR REDUCING VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTION OR COLONIZATION | MOAZZAMI, NAGHMEH NINA | 1652 | §103 | Final Rejection | — | Pending | Dec 13, 2021 |
| 17611805 | METHODS FOR PREDICTING RESPONSIVENESS OF CANCER TO FERROPTOSIS-INDUCING THERAPIES | BAUSCH, SARAE L | 1699 | §103§112 | Final Rejection | — | Pending | Nov 16, 2021 |
| 17428322 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | PERSONS, JENNA L | 1637 | §112 | Final Rejection | 85d overdue | Pending | Aug 04, 2021 |
| 17426728 | SENOLYTIC CAR-T CELLS TARGETING UPAR, A CELL SURFACE AND SECRETED SENESCENCE BIOMARKER | DIBRINO, MARIANNE | 1641 | §102 | Non-Final OA | 79d | Pending | Jul 29, 2021 |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 7d | Pending | Mar 09, 2021 |
| 17259800 | METHODS OF USING PHARMACOLOGIC INHIBITORS OF TYPE 2 CYTOKINE SIGNALING TO TREAT OR PREVENT PANCREATIC CANCER | BERHANE, SELAM | 1675 | §103 | Non-Final OA | 89d overdue | Pending | Jan 12, 2021 |
| 16979396 | METHODS OF SELECTING T CELL LINE FOR ADOPTIVE CELLULAR THERAPY | CHASE, CAROL ANN | 1646 | §112Other | Final Rejection | 41d | Pending | Sep 09, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial